Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BIPINKUMAR AMIN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1568415628
CMS profile
70966
Location
WATERTOWN, SD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$75,679.78

220 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BIPINKUMAR AMIN

NPI 1568415628 · CMS profile ID 70966

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WATERTOWN, SD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568415628?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BIPINKUMAR AMIN, NPI 1568415628, CMS profile ID 70966. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568415628?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BIPINKUMAR AMIN, NPI 1568415628, CMS profile ID 70966. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568415628?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BIPINKUMAR AMIN, NPI 1568415628, CMS profile ID 70966, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1568415628?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

220 matching records · $75,679.78 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 220 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 220.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca UK Limited $75.2705/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685088975 CMS
AstraZeneca UK Limited $22.0005/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685134711 CMS
AstraZeneca UK Limited $134.5705/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685159417 CMS
AstraZeneca UK Limited $13.5005/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685261613 CMS
AstraZeneca UK Limited $680.1005/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685357103 CMS
AstraZeneca UK Limited $53.6005/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685494959 CMS
AstraZeneca UK Limited $202.5605/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685640655 CMS
AstraZeneca UK Limited $86.4205/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685785047 CMS
Janssen Biotech, Inc. $500.0005/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658303943 CMS
Ipsen Biopharmaceuticals, Inc $12.5505/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640626241 CMS
Helsinn Therapeutics (U.S.), Inc. $12.6005/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655944019 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.0805/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697390513 CMS
Celgene Corporation $15.1105/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672778359 CMS
Amgen Inc. $17.9004/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662212477 CMS
AstraZeneca Pharmaceuticals LP $49.9904/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685194269 CMS
AstraZeneca Pharmaceuticals LP $31.0904/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685206543 CMS
AstraZeneca Pharmaceuticals LP $26.9604/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685259965 CMS
AstraZeneca Pharmaceuticals LP $69.6004/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685354751 CMS
AstraZeneca Pharmaceuticals LP $24.0004/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685591967 CMS
AstraZeneca Pharmaceuticals LP $89.5004/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685660895 CMS
AstraZeneca Pharmaceuticals LP $26.9604/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685744731 CMS
AstraZeneca Pharmaceuticals LP $444.0404/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685931279 CMS
AstraZeneca Pharmaceuticals LP $257.1104/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685934623 CMS
AstraZeneca Pharmaceuticals LP $18.2904/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685940075 CMS
AstraZeneca Pharmaceuticals LP $104.0004/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685960705 CMS
Pharmacyclics LLC, An AbbVie Company $59.4304/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705663 CMS
Pharmacyclics LLC, An AbbVie Company $86.5204/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705665 CMS
Pharmacyclics LLC, An AbbVie Company $3,000.0004/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705667 CMS
Pharmacyclics LLC, An AbbVie Company $176.1304/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705669 CMS
Pharmacyclics LLC, An AbbVie Company $10.5804/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705671 CMS
Pharmacyclics LLC, An AbbVie Company $796.6104/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705673 CMS
Pharmacyclics LLC, An AbbVie Company $1,175.9704/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705675 CMS
Pharmacyclics LLC, An AbbVie Company $232.0004/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705677 CMS
Pharmacyclics LLC, An AbbVie Company $35.0004/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665705679 CMS
Novocure Inc. $27.8604/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 677573149 CMS
Daiichi Sankyo Inc. $12.4404/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695317225 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.4504/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700459115 CMS
TESARO, Inc. $43.1404/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675553761 CMS
TESARO, Inc. $12.0703/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675553759 CMS
Clovis Oncology, Inc. $11.7103/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688686223 CMS
Celgene Corporation $1,350.0003/21/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672736089 CMS
Celgene Corporation $32.3403/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672767575 CMS
Merck Sharp & Dohme Corporation $15.3803/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695354981 CMS
Ipsen Biopharmaceuticals, Inc $0.4403/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753970984 CMS
Ipsen Biopharmaceuticals, Inc $8.6303/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753971102 CMS
Teva Pharmaceuticals USA, Inc. $12.7903/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697798177 CMS
Celgene Corporation $8.6903/07/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672737515 CMS
Celgene Corporation $11.0503/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672751209 CMS
Celgene Corporation $0.9303/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672757467 CMS
PFIZER INC. $15.7303/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671885233 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $75,679.78 220
PY2020 $12,949.51 40
PY2021 $39,118.77 91
PY2022 $59,773.78 124
PY2023 $31,590.01 84
PY2024 $55,344.11 152
PY2025 $17,230.33 60

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $348,496.76 29
PY2024 Principal investigator $91,145.03 13
PY2023 Principal investigator $80,039.09 15
PY2022 Principal investigator $60,928.27 21
PY2021 Principal investigator $128,350.76 42
PY2020 Principal investigator $248,597.24 66
PY2019 Principal investigator $64,073.92 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 12/29/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337067
Principal investigator 1 BeOne Medicines Ltd. $8,797.00 11/18/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190341879
Principal investigator 1 BeOne Medicines Ltd. $3,236.00 11/12/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190334343
Principal investigator 1 BeOne Medicines Ltd. $9,981.00 11/12/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190341876
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 11/03/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337107
Principal investigator 1 BeOne Medicines Ltd. $1,138.00 10/21/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1190335740
Principal investigator 1 BeOne Medicines Ltd. $4,332.00 09/30/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190334328
Principal investigator 1 BeOne Medicines Ltd. $15,720.00 09/05/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336793
Principal investigator 1 BeOne Medicines Ltd. $8,841.00 08/19/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190334334
Principal investigator 1 AstraZeneca Pharmaceuticals LP $500.00 08/01/2025 Non-covered Recipient Entity
PRAIRIE LAKES HEALTHCARE SYSTEM
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185547953
Principal investigator 1 BeOne Medicines Ltd. $11,584.00 07/22/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190334338
Principal investigator 1 BeOne Medicines Ltd. $25,838.16 06/26/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342258
Principal investigator 1 BeOne Medicines Ltd. $15,720.00 06/25/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190342283
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,384.50 06/13/2025 Non-covered Recipient Entity
Prairie Lakes Hospital
BAY 112233, A phase IV long-term follow-up study to define the safety profile of radium-223 dichloride. No dispute reported 06/30/2026 1225407254
Principal investigator 1 BeOne Medicines Ltd. $27,878.00 06/03/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190326450
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 05/30/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336733
Principal investigator 1 BeiGene, Ltd. $3,580.00 05/20/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323040
Principal investigator 1 AstraZeneca UK Limited $725.00 05/14/2025 Non-covered Recipient Entity
PRAIRIE LAKES HEALTHCARE SYSTEM
A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) No dispute reported 06/30/2026 1185547951
Principal investigator 1 BeiGene, Ltd. $1,439.81 04/21/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321852
Principal investigator 1 BeiGene, Ltd. $8,612.72 04/21/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321854
Principal investigator 1 BeiGene, Ltd. $1,879.04 04/21/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321856
Principal investigator 1 BeiGene, Ltd. $4,697.60 04/21/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321858
Principal investigator 1 BeiGene, Ltd. $15,720.00 04/21/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325236
Principal investigator 1 BeiGene, Ltd. $31,440.00 04/17/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323578
Principal investigator 1 BeiGene, Ltd. $1,439.81 04/17/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323580
Principal investigator 1 BeiGene, Ltd. $25,838.16 04/17/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323582
Principal investigator 1 BeiGene, Ltd. $7,516.16 04/17/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323584
Principal investigator 1 BeiGene, Ltd. $14,092.80 04/17/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323586
Principal investigator 1 BeiGene, Ltd. $2,246.00 03/25/2025 Non-covered Recipient Entity
Prairie Lakes Health Care System, Inc.
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) No dispute reported 06/30/2026 1190320250